These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 23615782)

  • 1. Remarks on the Asia Pacific Meeting of Vasculitis and ANCA Workshop 2012.
    Suzuki K
    Clin Exp Nephrol; 2013 Oct; 17(5):599-602. PubMed ID: 23615782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-neutrophil cytoplasmic antibody-associated vasculitis, large vessel vasculitis and Kawasaki disease in Japan.
    Kobayashi S; Fujimoto S; Takahashi K; Suzuki K
    Kidney Blood Press Res; 2010; 33(6):442-55. PubMed ID: 21071954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Twenty-five years of European Union collaboration in ANCA-associated vasculitis research.
    Jayne D; Rasmussen N
    Nephrol Dial Transplant; 2015 Apr; 30 Suppl 1():i1-7. PubMed ID: 25805742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-neutrophil Cytoplasmic Antibodies (ANCA) as Disease Activity Biomarkers in a "Personalized Medicine Approach" in ANCA-Associated Vasculitis.
    Osman MS; Tervaert JWC
    Curr Rheumatol Rep; 2019 Dec; 21(12):76. PubMed ID: 31879818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ANCA-associated vasculitis.
    Kitching AR; Anders HJ; Basu N; Brouwer E; Gordon J; Jayne DR; Kullman J; Lyons PA; Merkel PA; Savage COS; Specks U; Kain R
    Nat Rev Dis Primers; 2020 Aug; 6(1):71. PubMed ID: 32855422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myeloperoxidase anti-neutrophil cytoplasmic antibody affinity is associated with the formation of neutrophil extracellular traps in the kidney and vasculitis activity in myeloperoxidase anti-neutrophil cytoplasmic antibody-associated microscopic polyangiitis.
    Yoshida M; Yamada M; Sudo Y; Kojima T; Tomiyasu T; Yoshikawa N; Oda T; Yamada M
    Nephrology (Carlton); 2016 Jul; 21(7):624-9. PubMed ID: 26833773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical characteristics of patients with vasculitis positive for anti-neutrophil cytoplasmic antibody targeting both proteinase 3 and myeloperoxidase: a retrospective study.
    Kim SM; Choi SY; Kim SY; Kim J
    Rheumatol Int; 2019 Nov; 39(11):1919-1926. PubMed ID: 31552433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ANCA-Associated Vasculitis: Core Curriculum 2020.
    Geetha D; Jefferson JA
    Am J Kidney Dis; 2020 Jan; 75(1):124-137. PubMed ID: 31358311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. "How I treat" autoimmune diseases: State of the art on the management of rare rheumatic diseases and ANCA-associated systemic idiopathic vasculitis.
    Roccatello D
    Autoimmun Rev; 2017 Oct; 16(10):995-998. PubMed ID: 28780080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antineutrophil cytoplasmic antibody-associated vasculitides: a scientometric approach visualizing worldwide research activity.
    Gerber A; Klingelhoefer D; Groneberg D; Bundschuh M
    Int J Rheum Dis; 2014 Sep; 17(7):796-804. PubMed ID: 24702861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of positive anti-neutrophil cytoplasmic antibodies without evidence of anti-neutrophil cytoplasmic antibodies-associated vasculitis.
    Bornstein G; Ben-Zvi I; Furie N; Grossman C
    Int J Rheum Dis; 2019 May; 22(5):940-945. PubMed ID: 30729688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteinase 3-ANCA Vasculitis versus Myeloperoxidase-ANCA Vasculitis.
    Hilhorst M; van Paassen P; Tervaert JW;
    J Am Soc Nephrol; 2015 Oct; 26(10):2314-27. PubMed ID: 25956510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical features and treatment outcomes of otitis media with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (OMAAV): A retrospective analysis of 235 patients from a nationwide survey in Japan.
    Harabuchi Y; Kishibe K; Tateyama K; Morita Y; Yoshida N; Kunimoto Y; Matsui T; Sakaguchi H; Okada M; Watanabe T; Inagaki A; Kobayashi S; Iino Y; Murakami S; Takahashi H; Tono T
    Mod Rheumatol; 2017 Jan; 27(1):87-94. PubMed ID: 27166750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can antineutrophil cytoplasmic antibody levels be used to inform treatment of pauci-immune vasculitis?
    Fussner LA; Specks U
    Curr Opin Rheumatol; 2015 May; 27(3):231-40. PubMed ID: 25775187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Personalized Medicine in ANCA-Associated Vasculitis ANCA Specificity as the Guide?
    Wallace ZS; Stone JH
    Front Immunol; 2019; 10():2855. PubMed ID: 31867013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunopathogenesis of ANCA-Associated Vasculitis.
    Kronbichler A; Lee KH; Denicolò S; Choi D; Lee H; Ahn D; Kim KH; Lee JH; Kim H; Hwang M; Jung SW; Lee C; Lee H; Sung H; Lee D; Hwang J; Kim S; Hwang I; Kim DY; Kim HJ; Cho G; Cho Y; Kim D; Choi M; Park J; Park J; Tizaoui K; Li H; Smith L; Koyanagi A; Jacob L; Gauckler P; Shin JI
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33023023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cholesterol Emboli Co-Existing with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis in a 76-Year-Old Woman.
    Kojima R; Harada M; Yamaguchi A; Hashimoto K; Kamijo Y
    Tohoku J Exp Med; 2020 May; 251(1):61-68. PubMed ID: 32475887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Introduction, epidemiology and classification of vasculitis.
    Watts RA; Robson J
    Best Pract Res Clin Rheumatol; 2018 Feb; 32(1):3-20. PubMed ID: 30526896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vasculitis in New Zealand.
    de Zoysa JR
    Clin Exp Nephrol; 2013 Oct; 17(5):712-714. PubMed ID: 23180039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vasculitis research: Current trends and future perspectives.
    Misra DP; Naidu GSRSNK; Agarwal V; Sharma A
    Int J Rheum Dis; 2019 Jan; 22 Suppl 1():10-20. PubMed ID: 30168260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.